Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VK 0612

Drug Profile

VK 0612

Alternative Names: MB 07803; VK-0612

Latest Information Update: 16 May 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Viking Therapeutics
  • Class Amino acids; Antihyperglycaemics; Oxazoles; Thiazoles
  • Mechanism of Action Fructose bisphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 21 Mar 2017 Viking Therapeutics has patent protection and a pending patent application for VK 0612 in USA, China, Hong Kong, Israel, Korea, Mexico, India, Indonesia and New Zealand
  • 30 Jun 2015 VK 0612 is still in phase II trials for Type-2 diabetes mellitus in USA
  • 22 May 2014 VK 0612 licensed to Viking Therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top